PD-1/PD-L1
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
CSN28490 | PROTAC PD-1/PD-L1 degrader-1 | 2447066-37-5 | PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 degrader, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner. |
CSN17334 | BMS-202 | 1675203-84-5 | PD1-PDL1 inhibitor 2 is an inhibitor of the PD-1 (Programmed death- 1) PD-Ll (Programmed death-ligand 1) proteinprotein interaction with IC50 of 18 nM. |
CSN16212 | BMS-1 | 1675201-83-8 | PD-1PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1PD-L1 interaction with IC50 of 6 nM. |
CSN20302 | PD-1-PDL1 Inhibitor C1a HCl | 2108101-94-4 | PD-1-PD-L1 inhibitor C1a is a potential inhibitor of PD-1PD-L1 interaction which exhibits the structures capped on one side of the channel of PD-L1 homodimer |
CSN23861 | PD-1-IN-17 | 1673560-66-1 | PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1]. |
CSN24495 | BMS-1166 | 1818314-88-3 | BMS-1166 can disrupt PD-1/PD-L1 interaction with IC50 value of 1.4nM. It can antagonize the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation. |
CSN26733 | BMS-1001 hydrochloride | 2113650-04-5 | BMS-1001 HCl is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 HCl exhibits low-toxicity in cells. BMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. |
CSN24471 | CA-170 | 1673534-76-3 | AUPM-170 is one of CA-170 analogues extracted from patent WO 2015033299 A1, compound example 4. |